Sign in to view content

Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections

Nancy M. Holekamp, MD, FASRS

Video
Published 2020

Related

Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
Annual Meeting Talks
2020
Treatment Patterns and Visual and Health Function in Neovascular Age-Related Macular Degeneration (nAMD): Medicare Current Beneficiary Survey Analysis
Ferhina S Ali, MD, MPH
Annual Meeting Talks
2021
Clinical Evaluation and PK/PD Modeling of the DARPin Therapeutic Abicipar for the Treatment of Neovascular Age‐Related Macular Degeneration
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more